DC-NANOCHON
Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round.
The round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others.
Nanochon intends to use the funds to initiate its first in human clinical trials in the US in 2024, deepen research and development efforts, expand the company’s patent profile and grow its team.
“We’re thrilled to close our funding round and begin our clinical program,” says Ben Holmes, CEO and co-founder. “Securing this funding is one step closer towards achieving Nanochon’s goals of eliminating the need for knee replacements, and greatly shifting the paradigm of arthritic joint care.”
Nanochon will initiate a phase I trial in the US this year for its patented knee implant Chondrograft™. The device requires only minimally invasive surgery to regrow damaged cartilage and bone to stave off the need for full knee replacements which are costly and have a long recovery time.
Holmes follows, “We’ve had fantastic success in our animal studies and we’re very optimistic about future implications in human knees and other joints.”
Nanochon is a biotech and medical device company focused on developing innovative orthopedic solutions. Chondrograft™ is a minimally-invasive implant that allows for immediate weight-bearing and motion – meaning less time spent recovering. Nanochon has the potential to deliver more successful and longer-lasting recovery for patients than current standard of care. Our mission is to develop a new approach to treat cartilage replacement and repair so that the hundreds of thousands of young, active patients with joint damage can return to their lifestyles without having to undergo costly and invasive short-term fixes.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240503575444/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celebrate Excellence: 2026 SPIE Prism Awards Open for Outstanding Photonics Products9.7.2025 18:07:00 CEST | Press release
The winners will be announced 21 January at SPIE Photonics West Applications are now open for the 2026 SPIE Prism Awards. The awards, presented by SPIE, the international society for optics and photonics, recognize the most innovative products on the market, across the growing range of optics and photonics applications. The annual industry event will celebrate its 18th anniversary on 21 January, during a gala evening at SPIE Photonics West. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709679785/en/ SPIE is now welcoming submissions for its 2026 Prism Awards. In 2026, award category areas will include biophotonics instruments, cameras and imaging systems, lasers, optical materials and components, quantum tech, sensors, test and measurement, and XR tech. And now in its third year, SPIE will showcase the SPIE Catalyst Award, recognizing for-profit companies with programs that expand workplace access and opportunity, streng
SK Capital Has Entered Into Exclusive Negotiations to Acquire LISI Group’s Medical Division9.7.2025 17:45:00 CEST | Press release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, today announced that its affiliate has entered into exclusive negotiations with LISI Group (Euronext: FII) to acquire LISI Group’s Medical division (“Lisi Medical” or the “Company”). The transaction remains subject to the approval of the competent antitrust authorities, foreign direct investment control authorities and to the information and consultation processes of the relevant employee representative bodies in accordance with applicable laws. As such, the transaction is expected to close in the second half of 2025. Lisi Medical is a leading MedTech CDMO focused on the production of high-precision metal components and assemblies serving global medical device original equipment manufacturers (“OEMs”). The Company’s products include instruments utilized in minimally invasive and robotic-assisted surgery as well as orthopedic implan
LambdaTest Enables Playwright Testing on iOS Real Devices to Enhance Mobile Test Accuracy9.7.2025 17:00:00 CEST | Press release
New capability enables QA teams to automate Playwright scripts on real iPhones and iPads for unmatched mobile testing precision LambdaTest, a GenAI-powered quality engineering platform, has announced support for Playwright testing on real iOS devices, enabling mobile web teams to run automated tests on actual iPhones and iPads using Safari. This update helps QA and engineering teams validate user experiences with far greater accuracy than simulators or emulators can offer. Testing mobile web apps on virtual environments often leads to discrepancies in real-world behavior such as missed touch interactions, inconsistent browser rendering, and undetected performance bottlenecks. LambdaTest now eliminates that uncertainty by allowing developers to execute Playwright tests on physical iOS devices. While Playwright itself does not natively support real iOS hardware, LambdaTest’s integration bridges that gap, providing seamless access to Apple’s Safari browser on real devices. Users can integ
Rimini Street to Report Second Quarter 2025 Financial Results on July 31, 20259.7.2025 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 31, 2025. The company will host a conference call and webcast on that date to discuss the second quarter 2025 results and the 2025 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709364967/en/ Rimini Street to Report Second Quarter 2025 Financial Results on July 31, 2025 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini St
Obsidian Security Expands Go-to-Market Leadership Team to Scale SaaS Protection in the Age of AI9.7.2025 15:00:00 CEST | Press release
Leading SaaS Security Platform Strengthens Executive Bench with Five Strategic Hires as Company Scales Ahead of Growth Funding Obsidian Security, the leading SaaS security platform trusted by global enterprises including Snowflake, T-Mobile, and Pure Storage, today announced the expansion of its go-to-market leadership team with five strategic appointments. These hires position Obsidian to scale its operations as the company addresses the rapidly evolving security challenges posed by agentic AI and accelerates toward long-term growth and IPO readiness. The company has appointed Alison Tierney as VP of Go-to-Market (GTM) Strategy, Corey Elinburg as Field Chief Technology Officer, Brian McHenry as Vice President (VP) of Worldwide Solutions Engineering, Tina Lei as VP of Revenue Marketing, and Tyler Mihevc to lead Mid-Market expansion. These appointments build upon Obsidian's recent hire of Chief Product Officer (CPO) Khanh Tran, former VP of Product Management at CrowdStrike, as the comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom